EX-99.1 2 ea177860ex99-1_sapiensinter.htm PRESS RELEASE

Exhibit 99.1

 

 

Sapiens Reports First Quarter 2023 Financial Results

 

May 3, 2023 – Sapiens International Corporation, (NASDAQ and TASE: SPNS), a leading global provider of software solutions for the insurance industry, today announced its financial results for the first quarter ended March 31, 2023.

 

Summary Results for First Quarter 2023 (USD in millions, except per share data)

 

   GAAP       Non-GAAP     
   Q1 2023   Q1 2022   % Change   Q1 2023   Q1 2022   % Change 
Revenue  $124.7   $117.7    6.0%  $124.8   $117.7    6.0%
Gross Profit  $53.0   $49.4    7.3%  $56.4   $52.9    6.5%
Gross Margin   42.5%   42.0%    50 bps    45.2%   45.0%    20 bps 
Operating Income  $18.9   $16.5    14.2%  $22.5   $20.8    8.4%
Operating Margin   15.1%   14.1%    100 bps    18.0%   17.6%    40 bps 
Net Income (*)  $14.2   $13.9    1.9%  $17.3   $17.3    -0.3%
Diluted EPS  $0.26   $0.25    4.0%  $0.31   $0.31    0.0%

 

(*)Attributable to Sapiens’ shareholders

 

“Sapiens delivered a strong first quarter, with operating profit increasing year-over-year by 8.4% on revenue growth of 6%, which resulted in an operating margin of 18.0%,” stated Roni Al-Dor, President and CEO of Sapiens. “Our diligence and extensive groundwork in North America are now paying off as the region returns to growth. In the first quarter revenue in North America increased by 2.8% compared to last year. We ended 2022 with significant enhancements in our products, delivery, and talent that helped us build a momentum that has carried over into 2023. We have already signed new deals for P&C, Life, and Reinsurance since the beginning of the year and are optimistic by the quality of our new business pipeline.

 

Mr. Al-Dor continued, “Revenue growth in the first quarter was driven by a year-over-year increase of 9.0% in Europe. Our customer-centric model, implemented globally, has consistently driven growth and profitability while generating cash flow.”

 

We are well-positioned to continue our positive momentum from the first quarter throughout the remainder of the year. We are increasing our full-year 2023 non-GAAP revenues to $507 million to $512 million compared to our previous guidance of $502 million to $507 million. We are also increasing the guidance for the full year 2023 non-GAAP operating margin to 17.8%-18.2%, compared to our previous guidance of 17.6% to 18.0%. These revised targets demonstrate our commitment to delivering outstanding results and driving sustained growth,” concluded Mr. Al-Dor.

 

Quarterly Results Conference Call

 

Management will host a conference call and webcast on May 3, 2023, at 9:30 a.m. Eastern Time (4:30 p.m. in Israel) to review and discuss Sapiens’ results. Please call the following numbers (at least 10 minutes before the scheduled time) to participate:

 

North America (toll-free): 1-888-642-5032
   
International: 972-3-918-0609
   
UK: 0-800-917-5108

 

The live webcast of the call can be viewed on Sapiens’ website at: https://www.sapiens.com/investor-relations/ir-events-presentations. A replay of the call will be available one business day following the completion of the event, at the same link for 90 days.

 

 

 

 

Non-GAAP Financial Measures

 

This press release contains the following non-GAAP financial measures: non-GAAP revenue, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income attributed to Sapiens shareholders, non-GAAP basic and diluted earnings per share, Adjusted EBITDA and Adjusted Free Cash-Flow.

 

Sapiens believes that these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to Sapiens’ financial condition and results of operations. The Company’s management uses these non-GAAP measures to compare the Company’s performance to that of prior periods for trend analyses, for purposes of determining executive and senior management incentive compensation and for budgeting and planning purposes. These measures are used in financial reports prepared for management and in quarterly financial reports presented to the Company’s board of directors. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends, and in comparing the Company’s financial measures with other software companies, many of which present similar non-GAAP financial measures to investors.

 

Non-GAAP financial measures consist of GAAP financial measures adjusted to exclude: Valuation adjustment on acquired deferred revenue, amortization of capitalized software development and other intangible assets, capitalization of software development, stock-based compensation, compensation related to acquisition and acquisition-related costs, restructuring and cost reduction costs, and tax adjustments related to non-GAAP adjustments.

 

Management of the Company does not consider these non-GAAP measures in isolation, or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations, as they reflect the exercise of judgment by management about which expenses and income are excluded or included in determining these non-GAAP financial measures.

 

To compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. Sapiens urges investors to review the reconciliation of its non-GAAP financial measures to the comparable GAAP financial measures, which it includes in press releases announcing quarterly financial results, including this press release, and not to rely on any single financial measure to evaluate the Company’s business.

 

Reconciliation tables of the most comparable GAAP financial measures to the non-GAAP financial measures used in this press release are included with the financial tables of this release.

 

The Company defines Adjusted EBITDA as net profit, adjusted to eliminate valuation adjustment on acquired deferred revenue, stock-based compensation expense, depreciation and amortization, capitalization of software development costs, compensation expenses related to acquisition and acquisition-related costs, restructuring and cost reduction costs, financial expense (income), provision for income taxes and other income (expenses). These amounts are often excluded by other companies as well, in order to help investors understand the operational performance of their business.

 

The Company uses Adjusted EBITDA as a measurement of its operating performance, because it assists in comparing the operating performance on a consistent basis by removing the impact of certain non-cash and non-operating items. Adjusted EBITDA reflects an additional way of viewing aspects of the operations that the Company believes, when viewed with the GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting its business. The Company uses Adjusted Free Cash-Flow as a measurement of its operating performance, and reconciles cash-flow from operating activities to Adjusted Free Cash-Flow, while reducing the amounts for capitalization of software development costs and capital expenditures. The Company adds back cash payments made for former acquisitions in respect of future performance targets and retention criteria as determined upon acquisition date of the respective acquired company, which were included in the cash-flow from operating activities. We believe that Adjusted Free Cash-Flow is useful in evaluating our business, because Adjusted Free Cash-Flow reflects the cash surplus available to fund the expansion of our business.

 

2

 

 

About Sapiens

 

Sapiens International Corporation (NASDAQ and TASE: SPNS) empowers the financial sector, with a focus on insurance, to transform and become digital, innovative, and agile. With more than 40 years of industry expertise, Sapiens’ cloud-based SaaS insurance platform offers pre-integrated, low-code capabilities across core, data and digital domains to accelerate our customers’ digital transformation. Serving over 600 customers in 30 countries, Sapiens offers insurers across property and casualty, workers’ compensation, and life insurance markets the most comprehensive set of solutions, from core to complementary, including Reinsurance, Financial & Compliance, Data & Analytics, Digital, and Decision Management. For more information visit www.sapiens.com or follow us on LinkedIn.

 

Investor and Media Contact

 

Yaffa Cohen-Ifrah
Chief Marketing Officer and Head of Investor Relations, Sapiens
Yaffa.cohen-ifrah@sapiens.com
+1 917-533-4782

 

 

 

Investors Contact

 

Brett Maas
Managing Partner, Hayden IR

 

+1 646-536-7331
Brett.Maas@HaydenIR.com

 

Kimberly Rogers
Managing Director, Hayden IR
+1 541-904-5075
kim@HaydenIR.com

 

 

3

 

 

Forward Looking Statements

 

Certain matters discussed in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, and are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “plan” and similar expressions. Such statements reflect our current views with respect to future events and are subject to certain risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers’ systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the recent novel coronavirus pandemic, which adversely affected our results of operations, or fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company. While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F, which we filled with the SEC on March 31, 2022, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.

 

4

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENT OF INCOME

U.S. dollars in thousands (except per share amounts)

 

   Three months ended 
   March 31, 
   2023   2022 
   (unaudited)   (unaudited) 
         
Revenue   124,721    117,695 
Cost of revenue   71,692    68,278 
           
Gross profit   53,029    49,417 
           
Operating expenses:          
Research and development, net   15,617    14,150 
Selling, marketing, general and administrative   18,519    18,719 
Total operating expenses   34,136    32,869 
           
Operating income   18,893    16,548 
           
Financial and other expenses (income), net   1,197    (348)
Taxes on income   3,330    2,938 
           
Net income   14,366    13,958 
           
Attributable to non-controlling interest   170    32 
           
Net income attributable to Sapiens’ shareholders   14,196    13,926 
           
Basic earnings per share   0.26    0.25 
           
Diluted earnings per share   0.26    0.25 
           
Weighted average number of shares outstanding used to compute basic earnings per share
(in thousands)
   55,156    55,093 
           
Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands)   55,570    55,630 

 

5

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND SUBSIDIARIES

 

RECONCILIATION OF GAAP TO NON-GAAP RESULTS

U.S. dollars in thousands (except per share amounts)

 

   Three months ended 
   March 31, 
   2023   2022 
   (unaudited)   (unaudited) 
         
GAAP revenue   124,721    117,695 
Valuation adjustment on acquired deferred revenue   55    23 
Non-GAAP revenue   124,776    117,718 
           
GAAP gross profit   53,029    49,417 
Revenue adjustment   55    23 
Amortization of capitalized software   1,431    1,471 
Amortization of other intangible assets   1,848    2,032 
Non-GAAP gross profit   56,363    52,943 
           
GAAP operating income   18,893    16,548 
Gross profit adjustments   3,334    3,526 
Capitalization of software development   (1,658)   (1,746)
Amortization of other intangible assets   1,076    1,244 
Stock-based compensation   863    931 
Acquisition-related costs (*)   6    267 
Non-GAAP operating income   22,514    20,770 
           
GAAP net income attributable to Sapiens’ shareholders   14,196    13,926 
Operating income adjustments   3,621    4,222 
Taxes on income   (564)   (850)
Non-GAAP net income attributable to Sapiens’ shareholders   17,253    17,298 

 

(*)Acquisition-related costs pertain to charges on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as tax, accounting and legal rendered until the acquisition date.

 

6

 

 

Adjusted EBITDA Calculation
U.S. dollars in thousands

 

   Three months ended 
   March 31, 
   2023   2022 
         
GAAP operating profit   18,893    16,548 
           
Non-GAAP adjustments:          
Valuation adjustment on acquired deferred revenue   55    23 
Amortization of capitalized software   1,431    1,471 
Amortization of other intangible assets   2,924    3,276 
Capitalization of software development   (1,658)   (1,746)
Stock-based compensation   863    931 
Compensation related to acquisition and acquisition-related costs   6    267 
           
Non-GAAP operating profit   22,514    20,770 
           
Depreciation   1,055    1,140 
           
Adjusted EBITDA   23,569    21,910 

 

Summary of NON-GAAP Financial Information
U.S. dollars in thousands (except per share amounts)

 

   Q1 2023   Q4 2022   Q3 2022   Q2 2022   Q1 2022 
                     
Revenues   124,776    119,486    119,019    118,605    117,718 
Gross profit   56,363    53,774    53,546    53,207    52,943 
Operating income   22,514    21,058    20,902    20,747    20,770 
Adjusted EBITDA   23,569    22,092    22,036    21,681    21,910 
Net income to Sapiens’ shareholders   17,253    18,022    16,871    14,979    17,298 
                          
Diluted earnings per share   0.31    0.32    0.30    0.27    0.31 

 

Non-GAAP Revenues by Geographic Breakdown
U.S. dollars in thousands

 

   Q1 2023   Q4 2022   Q3 2022   Q2 2022   Q1 2022 
                     
North America   50,371    50,801    49,555    48,154    49,009 
Europe   64,572    56,910    56,887    59,868    59,267 
Rest of the World   9,833    11,775    12,577    10,583    9,442 
                          
Total   124,776    119,486    119,019    118,605    117,718 

 

7

 

 

Non-GAAP Revenue breakdown

U.S. dollars in thousands

 

   Q1 2023   %   Q1 2022   % 
                 
Software products and re-occurring post-production services (*)   81,842    65.6%   75,625    64.2%
Pre-production implementation services (**)   42,934    34.4%   42,093    35.8%
                     
Total Revenues   124,776    100%   117,718    100%

 

   Q1 2023   Q1 2022 
         
Software products and re-occurring post-production services (*)   44,849    40,446 
Pre-production implementation services (**)   11,514    12,497 
           
Total Gross profit   56,363    52,943 
           
   Q1 2023   Q1 2022 
         
Software products and re-occurring post-production services (*)   54.8%   53.5%
Pre-production implementation services (**)   26.8%   29.7%
           
Gross margin   45.2%   45.0%

 

(*)Software products and re-occurring post-production services include mainly term license, maintenance, cloud solutions, subscription, and post-production services. This revenue stream is a mix of recurring and re-occurring in nature.

(**)Pre-production implementation services include mainly implementation services before go-live, which are one-time in nature.

 

Adjusted Free Cash-Flow
U.S. dollars in thousands

 

   Q1 2023   Q4 2022   Q3 2022   Q2 2022   Q1 2022 
                     
Cash-flow from operating activities   22,188    14,430    4,405    6,615    18,330 
Increase in capitalized software development costs   (1,658)   (1,238)   (1,492)   (1,621)   (1,746)
Capital expenditures   (634)   (400)   (1,047)   (803)   (453)
Free cash-flow   19,896    12,792    1,866    4,191    16,131 
                          
Cash payments attributed to acquisition-related costs(*) (**)   30    1,100    -    -    - 
                          
Adjusted free cash-flow   19,926    13,892    1,866    4,191    16,131 

 

(*)Included in cash-flow from operating activities

 

(**)Acquisition-related payments pertain to payments on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as, tax, accounting and legal rendered until the acquisition date.

 

8

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEET

U.S. dollars in thousands

 

   March 31,   December 31, 
   2023   2022 
   (unaudited)   (unaudited) 
         
ASSETS        
         
CURRENT ASSETS        
Cash and cash equivalents   116,654    160,285 
Short-term bank deposit   65,000    20,000 
Trade receivables, net and unbilled receivables   94,833    93,382 
Other receivables and prepaid expenses   11,624    11,640 
Total current assets   288,111    285,307 
           
LONG-TERM ASSETS          
Property and equipment, net   11,612    12,021 
Severance pay fund   3,672    3,996 
Goodwill and intangible assets, net   316,865    319,661 
Operating lease right-of-use assets   27,439    33,688 
Other long-term assets   15,619    13,671 
Total long-term assets   375,207    383,037 
           
TOTAL ASSETS   663,318    668,344 
           
LIABILITIES AND EQUITY          
           
CURRENT LIABILITIES          
Trade payables   2,467    9,415 
Current maturities of Series B Debentures   19,796    19,796 
Accrued expenses and other liabilities   80,911    76,962 
Current maturities of operating lease liabilities   6,883    9,063 
Deferred revenue   38,920    30,720 
Total current liabilities   148,977    145,956 
           
LONG-TERM LIABILITIES          
Series B Debentures, net of current maturities   39,493    59,275 
Deferred tax liabilities   12,193    11,363 
Other long-term liabilities   13,097    13,312 
Long-term operating lease liabilities   24,686    28,432 
Redeemable non-controlling interest   87    89 
Accrued severance pay   6,903    7,063 
Total long-term liabilities   96,459    119,534 
           
EQUITY   417,882    402,854 
           
TOTAL LIABILITIES AND EQUITY   663,318    668,344 

 

9

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONSOLIDATED STATEMENT OF CASH FLOW
U.S. dollars in thousands

   For the three months ended March 31, 
   2023   2022 
   (unaudited)   (unaudited) 
Cash flows from operating activities:        
Net income   14,366    13,958 
Reconciliation of net income to net cash provided by operating activities:          
Depreciation and amortization   5,410    5,887 
Accretion of discount on series B debentures   14    18 
Capital (gain) loss from sale of property and equipment   (10)   7 
Stock-based compensation related to options issued to employees   863    931 
           
Net changes in operating assets and liabilities, net of amount acquired:          
Increase in trade receivables, net and unbilled receivables   (2,039)   (7,357)
Increase (decrease) in deferred tax liabilities, net   25    (471)
Decrease in other operating assets   1,257    959 
Decrease in trade payables   (7,014)   (34)
Increase (decrease) in other operating liabilities   1,197    (1,136)
Increase in deferred revenues   7,936    5,526 
Increase in accrued severance pay, net   183    42 
Net cash provided by operating activities   22,188    18,330 
           
Cash flows from investing activities:          
           
Purchase of property and equipment   (653)   (453)
Investment in deposits   (45,004)   (15,033)
Proceeds from sale of property and equipment   19    - 
Capitalized software development costs   (1,658)   (1,746)
Acquisition of intellectual property   (177)   - 
Net cash used in investing activities   (47,473)   (17,232)
           
Cash flows from financing activities:          
           
Repayment of series B debenture   (19,796)   (19,796)
Dividend to non-controlling interest   (47)   - 
Net cash used in financing activities   (19,843)   (19,796)
           
Effect of exchange rate changes on cash and cash equivalents   1,497    (236)
           
Increase (Decrease) in cash and cash equivalents   (43,631)   (18,934)
Cash and cash equivalents at the beginning of period   160,285    190,243 
           
Cash and cash equivalents at the end of period   116,654    171,309 

 

10

 

 

Debentures Covenants

 

As of March 31, 2023, Sapiens was in compliance with all of its financial covenants under the indenture for the Series B Debentures, based on having achieved the following in its consolidated financial results:

 

Covenant 1

 

Target shareholders’ equity (excluding non-controlling interest): above $120 million.
Actual shareholders’ equity (excluding non-controlling interest) equal to $415.4 million.

 

Covenant 2

 

Target ratio of net financial indebtedness to net capitalization (in each case, as defined under the indenture for the Company’s Series B Debentures) below 65%.
Actual ratio of net financial indebtedness to net capitalization equal to (41.17)%.

 

Covenant 3

 

Target ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is below 5.5.
Actual ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is equal to (1.36).

 

 

 11